The Effect of C-X-C Motif Chemokine 13 on Hepatocellular Carcinoma Associates with Wnt Signaling

Table 1

The clinical characteristics of subjects.

Parameters	Group A; Stages I-II; = 10	Group B; Stage III; = 8	Group C; Stage IV; = 14	HC; = 12
Age (years)	52 (46–67)	48 (44–68)	54 (50–75)	49 (43–74)
Gender: female/male	7/3	6/2	12/2	11/1
AFP (ng/mL)	58.2^*; (21.7–83.3)	152.7^*; (10.4–325.4)	194.6^*; (6.3–810)	7.1; (1.3–11.1)
ALT (U/L)	67.3^*; (18–243)	152.7^*; (98.1–305.8)	215.2^*; (145–712.6)	24.2; (13.6–27.8)
AST (U/L)	93.1^*; (34–737)	183.4^*; (79.2–385.2)	371^*; (127.1–963.7)	22.4; (15.3–32.1)
Rate of high level CXCL13 (%)	20	37.5	64.3	—

Data shown are real case number or median (range).
Normal values: AFP: <25 ng/mL; ALT: <40 IU/L; AST: <40 IU/L.
HC: healthy control.
—: not available.
versus the HC.